RxDoctor Payments Data

Lowell Anthony, MD

Medical Oncology · Lexington, KYNPI 1184622250

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 21.6%. Among medical oncology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$55,367in general payments, 2019–2025

Across 60 payments — averaging $922.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$12K
  • Curium US LLC$10K
  • Sun Pharmaceutical Industries Inc.$10K
  • Boehringer Ingelheim International GmbH$8K
  • Tersera Therapeutics LLC$7K
  • Boehringer Ingelheim$3K
  • plus $5K from 5 others
$466,243in research payments, 2019–2025

Across 30 payments — averaging $15,541 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$299K
  • Boehringer Ingelheim$116K
  • Exelixis Inc.$26K
  • Novartis$22K
  • Boehringer Ingelheim International GmbH$2K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$1K

What the payments were for

  • Consulting fees$32,02158%
  • Speaking & faculty fees$14,95827%
  • Travel & lodging$6,60512%
  • Food & beverage$1,7833%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,367 in reported general payments places this provider in the 95th percentile of 53 medical oncology providers in Kentucky.

See all medical oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$57,615
Medicare patients
226
Services billed
479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate42$967,853
XermeloTelotristat Etiprate43$402,393
Everolimus70$144,702
Somatuline DepotLanreotide Acetate11$89,421
Sunitinib Malate13$43,519
Abiraterone Acetate18$36,884
OrgovyxRelugolix12$29,717
CreonLipase/Protease/Amylase15$25,189
Octreotide Acetate59$23,266
Ondansetron Hcl54$3,021
Oxycodone Hcl63$1,162
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine21$704
Prochlorperazine Maleate26$401
Lorazepam26$201
Alprazolam16$190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$11,961$967,85342 claims
Tersera Therapeutics LLCXermelo$6,984$402,39343 claims
Ipsen Biopharmaceuticals, IncSomatuline Depot$187$89,42111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 53 medical oncology providers in Kentucky.

Other medical oncology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →